

Shu-Nan Qi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2836464/publications.pdf>

Version: 2024-02-01

44
papers

1,218
citations

471509

17
h-index

395702

33
g-index

53
all docs

53
docs citations

53
times ranked

1219
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 352-360.	10.7	258
2	Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 2905-2912.	7.0	105
3	Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. <i>Blood</i> , 2009, 114, 4771-4776.	1.4	83
4	Radiotherapy Alone With Curative Intent in Patients With Stage I Extranodal Nasal-Type NK/T-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1809-1815.	0.8	75
5	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 652-669.	0.8	71
6	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. <i>Leukemia</i> , 2021, 35, 130-142.	7.2	70
7	Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2017, 3, 83.	7.1	64
8	Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China. <i>Journal of Clinical Oncology</i> , 2020, 38, 3604-3614.	1.6	58
9	First-line non-â€œanthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. <i>Blood Advances</i> , 2020, 4, 3141-3153.	5.2	35
10	Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). <i>Radiotherapy and Oncology</i> , 2018, 129, 3-9.	0.6	30
11	The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 501-512.	0.8	30
12	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1064-1081.	0.8	26
13	Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. <i>American Journal of Hematology</i> , 2020, 95, 1047-1056.	4.1	25
14	Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. <i>Blood Advances</i> , 2018, 2, 2369-2377.	5.2	24
15	Diffuse large B-cell lymphoma. <i>Cancer</i> , 2009, 115, 4980-4989.	4.1	23
16	Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma. <i>JAMA Network Open</i> , 2019, 2, e190194.	5.9	23
17	Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). <i>Leukemia and Lymphoma</i> , 2019, 60, 2669-2678.	1.3	20
18	Patterns of Primary Tumor Invasion and Regional Lymph Node Spread Based on Magnetic Resonance Imaging in Early-Stage Nasal NK/T-cell Lymphoma: Implications for Clinical Target Volume Definition and Prognostic Significance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 50-59.	0.8	19

#	ARTICLE	IF	CITATIONS
19	LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5207-5217.	2.6	18
20	Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. <i>Leukemia</i> , 2020, 34, 2576-2591.	7.2	18
21	Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 61-70.	0.8	15
22	Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). <i>Cancer Medicine</i> , 2018, 7, 5952-5961.	2.8	14
23	Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, Tj ETQq1 1 0.78#314 rgBT /Over	1.0	14
24	Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. <i>Leukemia</i> , 2021, 35, 1671-1682.	7.2	14
25	Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG). <i>Aging</i> , 2019, 11, 8463-8473.	3.1	11
26	Radiomics Analysis of Fat-Saturated T2-Weighted MRI Sequences for the Prediction of Prognosis in Soft Tissue Sarcoma of the Extremities and Trunk Treated With Neoadjuvant Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 710649.	2.8	8
27	Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 605750.	2.8	7
28	POstmastectomy radioThErapy in Node-positIve breast cancer with or without Internal mAmmary nodal irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial. <i>BMC Cancer</i> , 2021, 21, 1185.	2.6	7
29	Dosimetric and Clinical Outcomes With Intensity Modulated Radiation Therapy After Chemotherapy for Patients With Early-Stage Diffuse Large B-cell Lymphoma of Waldeyer Ring. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 379-386.	0.8	6
30	Radiotherapy plays an important role in improving the survival outcome in patients with T1-2N1M0 breast cancer - a joint analysis of 4262 real world cases from two institutions. <i>BMC Cancer</i> , 2020, 20, 1155.	2.6	6
31	Safety and efficacy of preoperative chemoradiotherapy in fit older patients with intermediate or locally advanced rectal cancer evaluated by comprehensive geriatric assessment: A planned interim analysis of a multicenter, phase II trial. <i>Journal of Geriatric Oncology</i> , 2021, 12, 572-577.	1.0	6
32	First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 833-844.	0.8	6
33	Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2022, , .	2.8	6
34	Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis. <i>BMC Cancer</i> , 2022, 22, 212.	2.6	5
35	Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 212.	2.7	4
36	Prognosis and Prophylactic Regional Nodal Irradiation in Breast Cancer Patients With the First Isolated Chest Wall Recurrence After Mastectomy. <i>Frontiers in Oncology</i> , 2020, 10, 600525.	2.8	4

#	ARTICLE	IF	CITATIONS
37	Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571390.	2.8	2
38	Quality of Life After Partial or Whole-Breast Irradiation in Breast-Conserving Therapy for Low-Risk Breast Cancer: 1-Year Results of a Phase 2 Randomized Controlled Trial. <i>Frontiers in Oncology</i> , 2021, 11, 738318.	2.8	2
39	Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2136116.	5.9	2
40	Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1303-1309.	1.8	1
41	Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 447-456.	2.2	1
42	Can fit elderly patients evaluated by comprehensive geriatric assessment with intermediate or locally advanced rectal cancer receive preoperative chemoradiotherapy? An interim analysis of a multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15688-e15688.	1.6	1
43	Phase II clinical trial of first-line combination of radiation followed by gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy for early-stage extranodal natural killer/T-cell lymphoma with unfavorable prognostic factors: The GREEN study (NCT02276248).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7540-7540.	1.6	0
44	Development and Validation of an MRI-Based Nomogram Model for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 784156.	2.8	0